Filing Details
- Accession Number:
- 0001179110-22-003077
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-05-18 17:12:28
- Reporting Period:
- 2022-05-16
- Accepted Time:
- 2022-05-18 17:12:28
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1551152 | Abbvie Inc. | ABBV | Pharmaceutical Preparations (2834) | 320375147 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1609447 | Michael Severino | 1 N. Waukegan Road North Chicago IL 60064 | Vice Chairman | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.01 Par Value | Acquisiton | 2022-05-16 | 70,879 | $61.36 | 222,982 | No | 4 | M | Direct | |
| Common Stock, $0.01 Par Value | Acquisiton | 2022-05-16 | 29,121 | $79.02 | 252,103 | No | 4 | M | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2022-05-16 | 46,273 | $154.04 | 205,830 | No | 4 | S | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2022-05-16 | 53,327 | $154.80 | 152,503 | No | 4 | S | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2022-05-16 | 400 | $155.44 | 152,103 | No | 4 | S | Direct | |
| Common Stock, $0.01 Par Value | Acquisiton | 2022-05-17 | 35,364 | $79.02 | 187,467 | No | 4 | M | Direct | |
| Common Stock, $0.01 Par Value | Acquisiton | 2022-05-17 | 64,636 | $93.50 | 252,103 | No | 4 | M | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2022-05-17 | 43,621 | $153.43 | 208,482 | No | 4 | S | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2022-05-17 | 54,279 | $154.49 | 154,203 | No | 4 | S | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2022-05-17 | 2,100 | $155.27 | 152,103 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Option (Right to Buy) | Disposition | 2022-05-16 | 70,879 | $61.36 | 70,879 | $61.36 |
| Common Stock | Option (Right to Buy) | Disposition | 2022-05-16 | 29,121 | $79.20 | 29,121 | $79.02 |
| Common Stock | Option (Right to Buy) | Disposition | 2022-05-17 | 35,364 | $79.02 | 35,364 | $79.02 |
| Common Stock | Option (Right to Buy) | Disposition | 2022-05-17 | 64,636 | $93.50 | 64,636 | $93.50 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2018-02-16 | 2027-02-15 | No | 4 | M | Direct |
| 35,364 | 2020-02-21 | 2029-02-20 | No | 4 | M | Direct |
| 0 | 2020-02-21 | 2029-02-20 | No | 4 | M | Direct |
| 49,930 | 2021-02-20 | 2030-02-19 | No | 4 | M | Direct |
Footnotes
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.38 to $154.37 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.38 to $154.81 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at a price of $155.44. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.95 to $153.92 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.02 to $155.00 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at a price of $155.27. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
Billionaire Hedge Funds
